secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-08-04T20:09:52+00:00
Accession:  0001193125-26-332802
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q2 revenue $214M, net loss narrows to $0.90/share; reaffirms 2026 guidance
--------------------------------------------------------------------------------

- Q2 total revenue $214M (up 28% YoY); Crysvita $156M, Dojolvi $27M, Evkeeza $21M, Mepsevii $10M.
- Net loss $92M ($0.90/share) vs $115M ($1.17) in Q2 2025; operating expenses $289M.
- Reaffirms FY2026 revenue guidance $730M-$760M; combined R&D/SG&A flat to slightly down vs 2025; on track for profitability in 2027.
- Upcoming catalysts: PDUFA for DTX401 (Aug 23) and UX111 (Sep 19); GTX-102 Phase 3 data in Sep/Oct 2026.
- Cash $436M; net cash used in operations $97M in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-332802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer